List view / Grid view




New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance

25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…